{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:00:01Z","timestamp":1785312001372,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":752,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jtct.2021.01.025","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T05:30:41Z","timestamp":1612675841000},"page":"408.e1-408.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1016","volume":"27","author":[{"given":"Andreas","family":"Rank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine","family":"Simand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Santarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mistrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2021.01.025_bib0001","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2021.01.025_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11899-017-0371-4","article-title":"Who should receive a transplant for acute lymphoblastic leukaemia?","volume":"12","author":"Dhawan","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.jtct.2021.01.025_bib0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","volume":"20","author":"de Lima","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.01.025_bib0004","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.01.025_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2021.01.025_bib0006","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2021.01.025_bib0007","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2021.01.025_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2021.01.025_bib0009","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2021.01.025_bib0010","first-page":"763","article-title":"Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation","volume":"89","author":"Rihn","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.01.025_bib0011","unstructured":"https:\/\/www.ebmt.org\/Contents\/Data-Management\/Registrystructure\/MED-ABdatacollectionforms\/Pages\/MED-AB-data-collection-forms.aspx#HSCTManuals. 2021"},{"key":"10.1016\/j.jtct.2021.01.025_bib0012","unstructured":"https:\/\/www.ebmt.otg\/ebmt\/documents\/nih-defined-gvhd. 2021"},{"issue":"7","key":"10.1016\/j.jtct.2021.01.025_bib0013","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","article-title":"Transplant outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study","volume":"24","author":"Sengsayadeth","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.01.025_bib0014","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bmt.2015.221","article-title":"Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes","volume":"51","author":"Vrhovac","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"31","key":"10.1016\/j.jtct.2021.01.025_bib0015","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2021.01.025_bib0016","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/bmt.2015.193","article-title":"Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years","volume":"50","author":"Andreola","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.01.025_bib0017","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2021.01.025_bib0018","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","article-title":"Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation","volume":"107","author":"Schroeder","year":"2018","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2021.01.025_bib0019","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.jtct.2021.01.025_bib0020","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2021.01.025_bib0021","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41409-018-0232-3","article-title":"Prevention and treatment of relapse after stem cell transplantation with immunotherapy","volume":"53","author":"G\u00f6kbuget","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.01.025_bib0022","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2021.01.025_bib0023","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2021.01.025_bib0024","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2021.01.025_bib0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bmt.1705888","article-title":"Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant","volume":"41","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:05Z","timestamp":1763002805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721006345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2666636721006345"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.01.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}